Direct Selling Self-Regulatory Council Recommends Elomir Discontinue Certain Earnings and Health-Related Product Claims

McLean, VA – December 12, 2023 – The Direct Selling Self-Regulatory Council (DSSRC) of BBB National Programs recommended that Elomir, Inc. modify or discontinue certain earnings and health-related product performance claims, including disease treatment claims for its Axis Klärity product. 

The advertising claims were made by Elomir, a multi-level marketing company that sells nutritional supplements, and its salesforce members. The inquiry was brought to DSSRC by a non-governmental advocacy group (NGO).

The challenged product performance claims include, but are not limited to:

  • “Axis Klärity helps to promote healthy joints, a mellow mood, focus and mental clarity and gut health”
  • “… blood sugar support, cognitive support, immune support; mood support; focus and clarity; stimulant free energy; stress relief; gut health”
  • “Emotional? Overwhelmed? Anxious? Foggy head? Feeling heavy?” / Image of testimonial with copy stating “the first time I took the strip was on a very emotionally charged day and honestly within 5 minutes the feeling of heaviness and overwhelm drifted away! I feel so inspired, have amazing clarity, feeling happy and my focus is zen like yet so sharp every time!”
  • “When you have stomach issues from years of stress, ulcers, and GERD, you look for ways to get your supplements into your system by bypassing your tummy. I just tried @Elomir Corporate #axisklarity and I am in love! Not sure what #NAC #curcumin or #bvitaminsforenergy do for your body? You’ll want to search it up! My chiropractor has had me taking these supplements for months to combat #inflammation & to help my fight off viruses. This strip is phenomenal! 💛🌻🌟 #gastricbypasscommunity #gastricbypassjourney #weightlossjouney #bariatriclife #bariatricbabe #bariatriccommunity #healthsupplements #bounty”
  • “Guess who beat DIABETES 🙌🏼 Unexpected news from my doctor this week! He asked what did I do differently. He was amazed by what I showed him 🟨 #diabetes #beatdiabetes.”
  • “What I have noticed that improved since being on Axis Klarity: better mood; better focus; better skin, no breakouts because my gut health is better; better sleep.”

 

Challenged earnings claims include, but are not limited to:

  • “Whether you want the chance to earn a little extra income to help pay your bills or build a long-term home-based business, the possibilities await you at ELOMIR.”
  • “#buildingmyretirment”
  • “multiple 7 figures [in commissions” and claims such as “[p]ay off 3 of our credit cards,” and “paid our house note”

 

Elomir participated in the DSSRC process in good faith and worked quickly to remove most of the earnings and health-related claims identified by the NGO, more than 70 claims. In at least five instances where a salesforce member was unresponsive to Elomir’s request to take down the claim, Elomir commented directly on the social media post to state that it contains unsubstantiated earnings or medical claims.   

After a thorough review of substantiation provided for the remaining health-related claims in question, DSSRC determined that though the evidence submitted outlines the promise or positive benefits of the individual ingredients contained in Elomir’s flagship product, Axis Klärity, the substantiation is insufficient to support the wide-ranging health-related product performance claims challenged in this inquiry. 

As a result, DSSRC recommended that Elomir discontinue the remaining challenged claims. 

Regarding the earnings claim “Earn a little extra income to help pay your bills and build a home-based business. We allow you to be your own boss and provide you with the compensation plan to help you meet your goals,” which remains available on the Elomir website, DSSRC remained concerned that such claim in the context presented on the reasonably conveys that the typical salesforce member may earn significant income through the Elomir business opportunity and recommended it be removed from the website. 

DSSRC appreciates Elomir for their ongoing efforts to remove or modify the rest of the claims from circulation.  

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of DSSRC decisions, visit the DSSRC Cases and Closures webpage.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

Following National Advertising Division Inquiry, Google Voluntarily Unlists Video Demonstrating Google Gemini Capabilities

New York, NY – September 12, 2024 – Google voluntarily unlisted a video demonstrating the capabilities of Google Gemini, its large language model artificial intelligence (AI) offering introduced in December 2023.

Read the Decision Summary
Decision

National Advertising Division Recommends Gruma Modify Sugar and Net Carbohydrate Label Claims

New York, NY – September 11, 2024 – In a challenge brought by competitor Olé, the National Advertising Division found certain “zero sugar” and “0G sugar” claims supported and recommended that Gruma Corporation, in connection with its tortilla product offerings, modify or discontinue other claims. 

Read the Decision Summary
Decision

Direct Selling Self-Regulatory Council Recommends MONAT Discontinue Earnings Claims

McLean, VA – September 5, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended MONAT Global discontinue certain earnings claims made on the MONAT website and by salesforce members on Facebook, Twitter/X, Instagram, and YouTube. 

Read the Decision Summary
Decision

National Advertising Division Refers HiSmile Teeth Whitening Product Claims to the Federal Trade Commission

New York, NY – August 29, 2024 – The National Advertising Division referred HiSmile to the Federal Trade Commission (FTC) and other regulatory authorities for review after HiSmile declined to provide an advertiser statement confirming it will comply with all of NAD’s recommendations.
Read the Decision Summary